Kevin C. Clark
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin C. Clark has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Anaeli Sandoval1 shared publication
- Chloe Simpson1 shared publication
Christopher M. Depner
Department of Health and Kinesiology University of Utah Salt Lake City Utah USA
1 shared publication- Danielle M. Ostendorf
Anschutz Health and Wellness Center, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, Colorado; Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; and Department of Kinesiology, Recreation and Sports Studies, University of Tennessee Knoxville, Knoxville, Tennessee (D.M.O.)
1 shared publication - Elizabeth A. Thomas
Division of Endocrinology, Metabolism, and Diabetes Department of Medicine University of Colorado Anschutz Medical Campus Aurora Colorado USA
1 shared publication - Emily B. Hill
Department of Pediatrics, Section of Nutrition, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
1 shared publication
Latest Publications
- Open Access
- 23 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e86281
Exploring the Feasibility, Acceptability, and Safety of a 4:3 Intermittent Fasting Weight Loss Program Among Stage I-III Breast Cancer Survivors With Overweight or Obesity: Protocol for a 6-Month Proof-of-Concept Feasibility Trial
Background: Mounting evidence underscores the adverse effects of excess body weight during cancer survivorship, yet many breast cancer survivors struggle to maintain a healthy weight (approximately 70% have overweight or obesity [OW/OB]). Daily caloric restriction with increased physical activity is the standard behavioral weight loss approach; however, many fail to achieve clinically meaningful (>5%) weight loss, emphasizing the need for innovative interventions. A recent investigation found that a behavioral weight loss program focusing on 4:3 intermittent fasting (4:3 IMF) produced 60% greater weight loss among healthy adults with OW/OB with no history of cancer than a program focused on daily caloric restriction. Given these promising results and the need for innovative weight loss strategies among breast cancer survivors, studies testing 4:3 IMF among breast cancer survivors are warranted. Objective: This investigation aimed to evaluate the feasibility, acceptability, and safety of a 4:3 IMF behavioral weight loss program tailored to breast cancer survivors, and to examine exploratory clinical outcomes (eg, body weight, diet adherence, and physical activity) in relation to prespecified thresholds that will inform whether adjustments to the program are needed prior to progression to a larger trial. Methods: In this proof-of-concept feasibility study, individuals with stage I-III breast cancer who have OW/OB and are post–primary therapy will enroll in a 6-month behavioral weight-loss intervention using a 4:3 IMF dietary strategy. Participants will complete a modified fast of approximately 500 kcal per day on 3 non–consecutive days per week, with ad libitum intake the other 4 days per week. Participants will receive virtual, group-based education from a registered dietitian nutritionist that includes a focus on cancer-specific nutrition guidelines. They will also receive in-person, individualized exercise support from an established exercise oncology program to target cancer-specific exercise guidelines. Intervention feasibility will be assessed via participant recruitment, retention, and education class attendance. Acceptability of Intervention Measure, Intervention Appropriateness Measure, Net Promoter Scores, and focus group interviews will be used to assess program acceptability. Proof-of-concept will be evaluated based on whether prespecified thresholds for changes in exploratory clinical outcomes are met. This information will be used to inform progression to a larger trial. Results: This study was funded in January 2022. Data collection began in May 2024 and is ongoing as of April 2026. Recruitment was completed in September 2025 with 31 participants. Study volunteers are currently participating in the 6-month intervention, with data collection anticipated to be completed by Summer 2026, data analysis to begin in Summer/Fall 2026, and initial study results expected by early 2027. Conclusions: This study aimed to examine feasibility, acceptability, and safety of a 4:3 IMF intervention among breast cancer survivors. Data from this study will be used to refine the 4:3 IMF intervention for delivery in a future randomized efficacy trial.
- 23 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e86281
Open AccessExploring the Feasibility, Acceptability, and Safety of a 4:3 Intermittent Fasting Weight Loss Program Among Stage I-III Breast Cancer Survivors With Overweight or Obesity: Protocol for a 6-Month Proof-of-Concept Feasibility Trial
Background: Mounting evidence underscores the adverse effects of excess body weight during cancer survivorship, yet many breast cancer survivors struggle to maintain a healthy weight (approximately 70% have overweight or obesity [OW/OB]). Daily caloric restriction with increased physical activity is the standard behavioral weight loss approach; however, many fail to achieve clinically meaningful (>5%) weight loss, emphasizing the need for innovative interventions. A recent investigation found that a behavioral weight loss program focusing on 4:3 intermittent fasting (4:3 IMF) produced 60% greater weight loss among healthy adults with OW/OB with no history of cancer than a program focused on daily caloric restriction. Given these promising results and the need for innovative weight loss strategies among breast cancer survivors, studies testing 4:3 IMF among breast cancer survivors are warranted. Objective: This investigation aimed to evaluate the feasibility, acceptability, and safety of a 4:3 IMF behavioral weight loss program tailored to breast cancer survivors, and to examine exploratory clinical outcomes (eg, body weight, diet adherence, and physical activity) in relation to prespecified thresholds that will inform whether adjustments to the program are needed prior to progression to a larger trial. Methods: In this proof-of-concept feasibility study, individuals with stage I-III breast cancer who have OW/OB and are post–primary therapy will enroll in a 6-month behavioral weight-loss intervention using a 4:3 IMF dietary strategy. Participants will complete a modified fast of approximately 500 kcal per day on 3 non–consecutive days per week, with ad libitum intake the other 4 days per week. Participants will receive virtual, group-based education from a registered dietitian nutritionist that includes a focus on cancer-specific nutrition guidelines. They will also receive in-person, individualized exercise support from an established exercise oncology program to target cancer-specific exercise guidelines. Intervention feasibility will be assessed via participant recruitment, retention, and education class attendance. Acceptability of Intervention Measure, Intervention Appropriateness Measure, Net Promoter Scores, and focus group interviews will be used to assess program acceptability. Proof-of-concept will be evaluated based on whether prespecified thresholds for changes in exploratory clinical outcomes are met. This information will be used to inform progression to a larger trial. Results: This study was funded in January 2022. Data collection began in May 2024 and is ongoing as of April 2026. Recruitment was completed in September 2025 with 31 participants. Study volunteers are currently participating in the 6-month intervention, with data collection anticipated to be completed by Summer 2026, data analysis to begin in Summer/Fall 2026, and initial study results expected by early 2027. Conclusions: This study aimed to examine feasibility, acceptability, and safety of a 4:3 IMF intervention among breast cancer survivors. Data from this study will be used to refine the 4:3 IMF intervention for delivery in a future randomized efficacy trial.
- 8 September 2025
- Published by Wiley in Obesity Reviews
- Vol. 27 (2) , e70017
Examining the Role of Sleep in Body Weight Regulation and Implications for Obesity Treatment: A Narrative Review
Despite significant public health efforts to counter the obesity epidemic, approximately 50% of US adults will have obesity by 2030. The cornerstone of obesity treatment is a behavioral intervention promoting negative energy balance via a reduced‐calorie diet and increased physical activity. Behavioral treatment also requires additional support to promote adherence to these recommended lifestyle changes. More recently, sleep has been recognized as an important component of body weight regulation due to its effects on physiological and behavioral determinants of energy balance. Therefore, sleep may represent a modifiable behavior to target during the behavioral treatment of obesity. This review summarizes existing clinical evidence on the influence of sleep on energy balance and body weight regulation in adults. The results of controlled laboratory studies as well as pragmatic clinical trials are reviewed. In addition, we identify existing gaps and future areas of research that are necessary to understand the role of sleep in behavioral treatments for obesity.
- 8 September 2025
- Published by Wiley in Obesity Reviews
- Vol. 27 (2) , e70017
Examining the Role of Sleep in Body Weight Regulation and Implications for Obesity Treatment: A Narrative Review
Despite significant public health efforts to counter the obesity epidemic, approximately 50% of US adults will have obesity by 2030. The cornerstone of obesity treatment is a behavioral intervention promoting negative energy balance via a reduced‐calorie diet and increased physical activity. Behavioral treatment also requires additional support to promote adherence to these recommended lifestyle changes. More recently, sleep has been recognized as an important component of body weight regulation due to its effects on physiological and behavioral determinants of energy balance. Therefore, sleep may represent a modifiable behavior to target during the behavioral treatment of obesity. This review summarizes existing clinical evidence on the influence of sleep on energy balance and body weight regulation in adults. The results of controlled laboratory studies as well as pragmatic clinical trials are reviewed. In addition, we identify existing gaps and future areas of research that are necessary to understand the role of sleep in behavioral treatments for obesity.